Friday, June 20th, 2025
Stock Profile: BIVI

BioVie Inc. (BIVI)

Market: NASD | Currency: USD

Address: 680 West Nye Lane

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease. The company develops BIV201 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered Show more




📈 BioVie Inc. Historical Chart






📊 Statistics





💰 Dividend History


Year Annual Yield (%) Total Amount Current Yield (%) Ex Date Pay Date Particulars
2024 - $0.100000 - 2024-08-06 - Stock split
Total Amount for 2024: $0.100000


📅 Earnings & EPS History for BioVie Inc.


DateReported EPS
2026-02-09 (estimated upcoming)-
2025-11-11 (estimated upcoming)-
2025-11-10 (estimated upcoming)-
2025-09-29 (estimated upcoming)-
2025-09-28 (estimated upcoming)-
2025-05-12-
2025-05-11-
2025-02-11-
2024-11-13-
2024-09-30-
2024-05-14-
2024-05-13-
2024-02-13-0.22
2024-02-12-0.22
2023-11-08-0.29
2023-11-07-0.29
2023-08-16-0.25
2023-08-15-0.25
2023-05-12-
2023-05-11-
2023-02-10-0.5
2023-02-09-0.5
2022-11-04-0.38
2022-11-03-0.38
2022-09-27-0.33
2022-09-26-0.33
2022-05-11-0.28
2022-05-10-0.28
2022-02-08-0.28
2022-02-07-0.28
2021-11-10-
2021-11-09-
2021-08-30-10.18
2021-08-29-10.18
2021-05-10-
2021-05-09-
2021-01-29-
2021-01-28-
2020-11-05-
2020-11-04-
2020-08-06-
2020-08-05-




📰 Related News & Research


No related articles found for "biovie inc".